Marc J. Kahn Named Dean of UNLV School of Medicine
Marc J. Kahn, MD, has been appointed the dean of the School of Medicine at the University of Nevada, Las Vegas (UNLV). Dr. Kahn previously served as senior associate dean at Tulane University School of Medicine. He succeeds Interim Dean John Fildes, MD.
“Dr. Kahn is an experienced leader and innovator who will continue the upward trajectory of our UNLV School of Medicine,” said Marta Meana, UNLV President.
Dr. Kahn currently serves as chair of the ASH Committee on Educational Affairs, as well as on the hematology board for the American Board of Internal Medicine. In addition to Dr. Kahn’s training in hematology and medical oncology, he holds an MBA with concentrations in finance and international business.
Source: UNLV press release, January 8, 2020.
David A. Tuveson is AACR President-Elect for 2020-2021
Members of the American Association for Cancer Research (AACR) have elected David A. Tuveson, MD, PhD, as their President-Elect for 2020-2021. He will assume the presidency in April 2021 at the AACR Annual Meeting in Washington, D.C.
Dr. Tuveson serves as director of the Cold Spring Harbor Laboratory Cancer Center in Cold Spring Harbor, New York, as well as chief scientist for the Lustgarten Foundation in Woodbury, New York, a nonprofit dedicated to pancreatic cancer research.
“Dr. Tuveson is a highly distinguished physician-scientist whose pioneering pancreatic cancer research has had an enormous impact on our basic understanding and treatment of this deadly disease,” said Margaret Foti, PhD, MD, CEO of AACR. “His scientific and clinical expertise, together with his visionary leadership and dedication to conquering cancer in all its forms, will be invaluable to the AACR as our organization continues to work toward the goal of preventing and curing all cancers.”
Source: AACR press release, April 21, 2020.
Two ASH Members Are Finalists for Service to America Medals
Two members of the American Society of Hematology (ASH) were selected as finalists for the Samuel J. Heyman Service to America Medals, also known as the “Sammies.” These awards are given to highlight the accomplishments of dedicated federal public servants.
The two ASH members who are finalists are John F. Tisdale, MD, Chief of Cellular and Molecular Therapeutics Branch of the National Heart, Lung, and Blood Institute, and Griffin P. Rodgers, MD, Director of the National Institute of Diabetes and Digestive and Kidney Diseases, along with the NIH’s cellular and molecular therapeutics team.
The team has been nominated for its work on the treatment of sickle cell disease (SCD). Its latest success comes from a small trial of a new gene therapy for SCD that delivers corrected genetic material to a patient’s bone marrow.
“Because of the work of Rodgers and Tisdale, research on sickle cell disease is no longer neglected,” said NIH Director Francis Collins, MD, PhD. “It’s some of the most exciting and groundbreaking science there is.”
The public can vote for the People’s Choice Winner until June 26 on the Service to America Medals website.
Source: Service to America Medals Announcement, May 4, 2020.
UNC School of Medicine Appoints New Chiefs of Hematology and Oncology
The University of North Carolina (UNC) School of Medicine has announced the realignment of its formerly combined Hematology/Oncology department into two distinct divisions. The school has appointed Jonathan Serody, MD, as Chief of Hematology, and Ethan Basch, MD, as Chief of Oncology, for the forthcoming departments.
“We’ve determined that having two divisions, tightly linked, will help us more efficiently manage administration for these subspecialties and position them for future growth,” said Ron Falk, MD, chair of the UNC Department of Medicine.
Dr. Serody serves as Associate Chief of Malignant Hematology, Bone Marrow Transplant, and Cellular Therapy and is Director of UNC’s Bone Marrow Transplantation and Cellular Therapy Program. He has also held leadership positions at ASH and has served on the editorial board of the Blood journal.
Dr. Basch is UNC’s Richard M. Goldberg Distinguished Professor in Medical Oncology and directs the Outcomes Research Program for UNC Lineberger. His research is focused clinically on the treatment of men with prostate cancer. He has served on the Board of Scientific Advisors of the National Cancer Institute and currently serves on ASCO’s board of directors.
Source: UNC Lineberger Press Release, April 14, 2020.
Robin Zon Receives ASCO Achievement Award
The American Society of Clinical Oncology (ASCO) has awarded Robin Zon, MD, the 2020 Distinguished Achievement Award, as part of the annual ASCO Awards.
Dr. Zon has worked in various aspects of hematology/oncology for more than 25 years, including patient care, research, policy, and advocacy. She serves as president of Michiana Hematology Oncology and has offered guidance to groups like the Institute of Medicine (now National Academy of Medicine) and the National Cancer Institute, advocating for patients with cancer and their caregivers.
“When I reflect upon my career, I celebrate how the evolving cancer care continuum has affected patients,” she said. “Along with improvements in partnering with patients, the outcomes have been amazing. It’s incredible how the story for patients with cancer has changed. I’ve been so honored to be a part of this transformation.”